By Chris Wack
Shares of Syndax Pharmaceuticals jumped 8% to $18 following the release of positive data from trials involving the use of revumenib in combination with standard of care agents for patients with nucleophosmin mutant and KMT2A-rearranged relapsed/refractory acute leukemias.
Revumenib, an oral menin inhibitor developed by Syndax Pharmaceuticals, has shown promising results in these trials.
The biopharmaceutical company revealed on Monday that revumenib has been well tolerated and has demonstrated clinical activity when combined with venetoclax/hypomethylating agents in both frontline and acute myeloid leukemia settings.
As of the data cutoff date of November 1st, a total of nine patients were enrolled in the study and their response was evaluated at the time of data collection. Remarkably, all nine patients achieved morphologic remission, resulting in an overall response rate of 100%.
Furthermore, the combination treatment showed good tolerability in this relapsed and refractory patient population, with no new safety concerns identified.
For more information, please contact Chris Wack.